Patent Number: 8,580,962

Title: Spiroheterocyclic compounds as mGlu5 antagonists

Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Inventors: Leonardi; Amedeo (Milan, IT), Motta; Gianni (Barlassina, IT), Riva; Carlo (Varese, IT), Guarneri; Luciano (Garbagnate Milanese, IT), Graziani; Davide (Milan, IT), De Toma; Carlo (Milan, IT), Karamfilova; Katia Dimitrova (Sesto San Giovanni, IT)

Assignee: Recordati Ireland Ltd.

International Classification: A61K 31/44 (20060101); C07D 213/00 (20060101)

Expiration Date: 2022-11-12 0:00:00